Literature DB >> 1436407

Tumor control after stereotactic radiosurgery in neurofibromatosis patients with bilateral acoustic tumors.

M E Linskey1, L D Lunsford, J C Flickinger.   

Abstract

During a 4-year interval, 17 patients with bilateral acoustic tumors (vestibular schwannomas) underwent unilateral stereotactic radiosurgery using a multisource gamma unit; 2 patients underwent radiosurgery of both tumors in separate sessions. Eleven patients with unoperated contralateral tumors served as concurrent controls to compare the effects of radiosurgery with the natural history of acoustic tumors. After radiosurgery, the tumor control and regression rates were 89.5 and 21.1%, respectively (median neuroimaging follow-up, 1.4 years; range, 0.3-3.9). The tumor regression rate increased to 40% for patients evaluated at least 12 months after radiosurgery. In comparison to the unoperated contralateral tumors, stereotactic radiosurgery achieved tumor control, as assessed by the ultimate change in tumor size at follow-up (P, 0.012), the change in tumor size over time (P, 0.006), and tumor growth rates (P, 0.003). This study provided convincing evidence that tumor stabilization after radiosurgery (as assessed by neuroimaging) truly represented tumor control. The incidence of delayed facial neuropathy after radiosurgery compared favorably with the incidence reported after microsurgical removal. Some hearing was preserved in one-third of the patients who had preoperative hearing, including three patients who were contralaterally deaf. Stereotactic radiosurgery should be considered as a primary surgical modality for many patients with neurofibromatosis Type II.

Entities:  

Mesh:

Year:  1992        PMID: 1436407     DOI: 10.1227/00006123-199211000-00002

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  7 in total

Review 1.  Radiation therapy and hearing loss.

Authors:  Niranjan Bhandare; Andrew Jackson; Avraham Eisbruch; Charlie C Pan; John C Flickinger; Patrick Antonelli; William M Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

2.  Acoustic Neuromas.

Authors:  Douglas Kondziolka; L. Dade Lunsford; John C. Flickinger
Journal:  Curr Treat Options Neurol       Date:  2002-03       Impact factor: 3.598

3.  Radiosurgery with the first Austrian cobalt-60 Gamma-unit. A one year experience.

Authors:  G Pendl; O Schröttner; G M Friehs; J Legat; K Leber; M Mokry; G Papaefthymiou; G Langmann
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

4.  Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis.

Authors:  J G Rowe; M W R Radatz; L Walton; T Soanes; J Rodgers; A A Kemeny
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

Review 5.  Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Authors:  Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

Review 6.  Facial nerve preservation after vestibular schwannoma Gamma Knife radiosurgery.

Authors:  Isaac Yang; Michael E Sughrue; Seunggu J Han; Shanna Fang; Derick Aranda; Steven W Cheung; Lawrence H Pitts; Andrew T Parsa
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

Review 7.  Diagnostics and therapy of vestibular schwannomas - an interdisciplinary challenge.

Authors:  Steffen Rosahl; Christopher Bohr; Michael Lell; Klaus Hamm; Heinrich Iro
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2017-12-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.